Skip to content

Exploratory research on treatment of acute and severe cerebral infarction using Bioboosti

Efficacy and safety of Bioboosti rehabilitation-assisting in patients with acute and severe cerebral infarction: a randomized, parallel controlled, double-blind exploratory trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017631
Enrollment
Unknown
Registered
2018-08-07
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute and severe cerebral infarction

Interventions

Sponsors

Beijing Tian Tan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Participant aged 35 to 70 year-old; 2) Admitted to our hospital within 7 days of onset the acute and severe cerebral infarction; 3) NIHSS score at onset was 8 to 24 points and the 1a, 1b, 1c of NIHSS was all 0 point; 4) Blood pressure higher than 180/105 mmHg at onset of cerebral infarction; 5) Participant (or their legal representatives) voluntarily participate in this trial and signed the Informed Consent Form (ICF).

Exclusion criteria

Exclusion criteria: 1) Pregnant women; 2) Participants with moderate and severe sleep apnea syndrome; 3) Participants with malignant tumor; 4) Participants with severe kidney and hematopoietic diseases; 5) Participants with severe/unstable angina, myocardial infarction, coronary/peripheral artery bypass graft, or participants with cardiac pacemaker; 6) Participants with diabetic foot disorders; 7) Other conditions that may cause the participants fail to complete the study or risk to the participants; 8) Participants who was unwilling or incapable to conduct the instructions of the rehabilitation program; 9) Participants with an expected survival of less than 90 days.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale;Modified Rankin Index;

Secondary

MeasureTime frame
NIHSS;CT perfusion improvement;TCD-MCA;

Countries

China

Contacts

Public ContactLiu Liping

Beijing Tian Tan Hospital, Capital Medical University

lipingsister@gmail.com+86 13331159535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026